Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00192517
Status:
COMPLETED
Last Update Posted:
2009-04-03
First Post:
2005-09-13
Brief Title:
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
A Phase II Randomized Double-Blind Placebo-Controlled Study of MEDI-522 a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to compare the effects on disease activity in the absence of systemic psoriasis therapy of 4 mgkg MEDI-522 versus placebo administered weekly by SC injection for 12 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None